Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects

Hdl Handle:
http://hdl.handle.net/10675.2/779
Title:
Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects
Authors:
Ding, Zhi-Chun ( 0000-0001-6322-8641 ) ; Zhou, Gang
Abstract:
Standard cytotoxic chemotherapy can initially achieve high response rates, but relapses often occur in patients and represent a severe clinical problem. As increasing numbers of chemotherapeutic agents are found to have immunostimulatory effects, there is a growing interest to combine chemotherapy and immunotherapy for synergistic antitumor effects and improved clinical benefits. Findings from recent studies suggest that highly activated, polyfunctional CD4+ effector T cells have tremendous potential in strengthening and sustaining the overall host antitumor immunity in the postchemotherapy window. This review focuses on the latest progresses regarding the impact of chemotherapy on CD4+ T-cell phenotype and function and discusses the prospect of exploiting CD4+ T cells to control tumor progression and prevent relapse after chemotherapy.
Citation:
Clin Dev Immunol. 2012 Feb 6; 2012:890178
Issue Date:
6-Feb-2012
URI:
http://hdl.handle.net/10675.2/779
DOI:
10.1155/2012/890178
PubMed ID:
22400040
PubMed Central ID:
PMC3286900
Type:
Article
ISSN:
1740-2530
Appears in Collections:
Georgia Cancer Center: Faculty Research and Presentations

Full metadata record

DC FieldValue Language
dc.contributor.authorDing, Zhi-Chunen_US
dc.contributor.authorZhou, Gangen_US
dc.date.accessioned2012-10-26T20:30:43Z-
dc.date.available2012-10-26T20:30:43Z-
dc.date.issued2012-02-6en_US
dc.identifier.citationClin Dev Immunol. 2012 Feb 6; 2012:890178en_US
dc.identifier.issn1740-2530en_US
dc.identifier.pmid22400040en_US
dc.identifier.doi10.1155/2012/890178en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/779-
dc.description.abstractStandard cytotoxic chemotherapy can initially achieve high response rates, but relapses often occur in patients and represent a severe clinical problem. As increasing numbers of chemotherapeutic agents are found to have immunostimulatory effects, there is a growing interest to combine chemotherapy and immunotherapy for synergistic antitumor effects and improved clinical benefits. Findings from recent studies suggest that highly activated, polyfunctional CD4+ effector T cells have tremendous potential in strengthening and sustaining the overall host antitumor immunity in the postchemotherapy window. This review focuses on the latest progresses regarding the impact of chemotherapy on CD4+ T-cell phenotype and function and discusses the prospect of exploiting CD4+ T cells to control tumor progression and prevent relapse after chemotherapy.en_US
dc.rightsCopyright © 2012 Z.-C. Ding and G. Zhou.en_US
dc.subjectReview Articleen_US
dc.titleCytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effectsen_US
dc.typeArticleen_US
dc.identifier.pmcidPMC3286900en_US
dc.contributor.corporatenameGHSU Cancer Center-
dc.contributor.corporatenameDepartment of Medicine-

Related articles on PubMed

All Items in Scholarly Commons are protected by copyright, with all rights reserved, unless otherwise indicated.